Abraham Ceesay, M.B.A.

Abraham Ceesay, M.B.A.

Chief Executive OfficeratRapport Therapeutics· In proxies 2023–2025

Pay in FY2025-36% from the year before · Rapport Therapeutics stock +71.0% the same year

Abraham Ceesay, M.B.A. was paid $6.3M in FY2025 (Dec), down 36%. Rapport Therapeutics stock rose 71.0% that year.

Pay$100 in the stock at the end of FY24 → $171
Pay is from the Summary Compensation Table of each Rapport Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Rapport TherapeuticsPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role +8%
  2. Pacira BioSciencesPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  3. Charles River LaboratoriesPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Rapport TherapeuticsDirector · 2 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?